Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 471-474

  Huang, R Stephanie ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer; Chemotherapy; Genome wide association study; Pharmacogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLUCURONOSYLTRANSFERASE 1A1; HISTONE DEACETYLASE INHIBITOR; IMATINIB; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

CANCER THERAPY; COPY NUMBER VARIATION; DRUG TARGETING; EPIGENETICS; GENE IDENTIFICATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; NONHUMAN; NOTE; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DRUG DISCOVERY; GENETIC MARKERS; GENOME, HUMAN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77950353917     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.11     Document Type: Note

References (23)

1. Weiner L: An overview of monoclonal antibody therapy of cancer. Semin. Oncol. 26(4 Suppl. 12), 41-50 (1999).
2. Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13), 4808-4817 (2008).
3. Ritter C, Arteaga C: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 30(1 Suppl. 1), 3-11 (2003).
4. Jain RK, Duda DG, Clark JW, Loeffer JS: Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Prac. Oncol. 3(1), 24-40 (2006).
5. Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459-5468 (2009).
6. Lennard L, Lilleyman J, Loon JV, Weinshilboum R: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336(8709), 225-229 (1990).
7. Hoskins J, Goldberg R, Qu P, Ibrahim J, McLeod H: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007).
8. Goetz MP, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of effcacy and hot fashes. J. Clin. Oncol. 23(36), 9312-9318 (2005).
9. Dolan ME, Newbold KG, Nagasubramanian R et al.: Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64(12), 4353-4356 (2004).
10. Watters JW, Kraja A, Meucci Ma, Province MA, McLeod HL: Genome-wide discovery of loci infuencing chemotherapy cytotoxicity. Proc. Natl Acad. Sci. USA 101(32), 11809-11814 (2004).
11. McPherson JD, Marra M, Hillier L et al.: A physical map of the human genome. Nature 409(6822), 934-941 (2001).
12. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008).
13. Morris S, Carey L: Gene expression profling in breast cancer. Curr. Opin. Oncol. 19(6), 547-551 (2007).
14. Thomas RK, Weir B, Meyerson M: Genomic approaches to lung cancer. Clin. Cancer Res. 12(14), S4384-S4391 (2006).
15. Holleman A, Den Boer Ml, De Menezes RX et al.: The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 107(2), 769-776 (2006).
16. Holleman A, Cheok M, Den Boer M et al.: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351(6), 533-542 (2004).
17. Potti A, Dressman HK, Bild A et al.: Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12(11), 1294-1300 (2006).
18. Huang RS, Duan S, Shukla SJ et al.: Identifcation of genetic variants contributing to cisplatin-induced cytotoxicity using a genome-wide approach. Am. J. Hum. Genet. 81(3), 427-437 (2007).
19. Huang Y-T, Heist RS, Chirieac LR et al.: Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J. Clin. Oncol. 27(16), 2660-2667 (2009).
20. Yang JJ, Bhojwani D, Yang W et al.: Genome-wide copy number profling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112(10), 4178-4183 (2008).
21. Zhang Y, Martens JWM, Yu JX et al.: Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res. 69(9), 3795-3801 (2009).
22. Duan S, Huang R, Zhang W et al.: Genetic architecture of transcript-level variation in humans. Am. J. Hum. Genet. 82(5), 1101-1113 (2008).
23. International Hapmap Consortium; Frazer K, Ballinger D, Cox DR et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).